Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study

Yoshiya Tanaka; Hideto Kameda; Kazuyoshi Saito; Yuko Kaneko; Eiichi Tanaka; Shinsuke Yasuda; Naoto Tamura; Keishi Fujio; Takao Fujii; Toshihisa Kojima; Tatsuhiko Anzai; Chikuma Hamada; Yoshihisa Fujino; Shinya Matsuda; Hitoshi Kohsaka

doi:10.1080/14397595.2019.1709681

Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study

Yoshiya Tanaka, Hideto Kameda, Kazuyoshi Saito, Yuko Kaneko, Eiichi Tanaka, Shinsuke Yasuda, Naoto Tamura, Keishi Fujio, Takao Fujii, Toshihisa Kojima, Tatsuhiko Anzai, Chikuma Hamada, Yoshihisa Fujino, Shinya Matsuda, Hitoshi Kohsaka

Department of Internal Medicine (Rheumatology)

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Objectives: We evaluated long-term control of rheumatoid arthritis (RA) in Japanese paid workers (PWs) and house workers (HWs) treated with subcutaneous tocilizumab (TCZ-SC) and explored factors affecting response to TCZ-SC regarding work productivity. Methods: This study collected data from patients with RA in the TCZ-SC +/− conventional synthetic disease-modifying antirheumatic drugs group. Factors affecting the response to tocilizumab regarding work productivity were explored using logistic regression. Differences in quality-adjusted life years (QALYs) between with/without response were analysed by a linear regression. Results: Data were analysed for 357/360 patients. Patients with a ≥ 75% improvement in activity impairment (AI) were considered responders. EuroQol-5 Dimension (EQ-5D), six-item Kessler psychological distress scale score (K6), Health Assessment Questionnaire Disability Index (HAQ-DI), and the patient’s disease global health by visual analogue scale were significant contributors to TCZ-SC response based on improvements in AI. Work Functioning Impairment Scale, presenteeism, EQ-5D, K6, and HAQ-DI significantly contributed to the improvement of overall work impairment in PWs. Shorter disease duration also was related to TCZ-SC response based on AI improvements. Responders had significantly larger mean QALYs than non-responders (difference = 0.2614; p <.001). Conclusions: These real-world clinical data support long-term work productivity control with TCZ-SC for biologic-naïve HWs and PWs with RA.

Original language	English
Pages (from-to)	42-52
Number of pages	11
Journal	Modern rheumatology
Volume	31
Issue number	1
DOIs	https://doi.org/10.1080/14397595.2019.1709681
Publication status	Published - 2021

Keywords

Activity impairment
patient-reported outcome
rheumatoid arthritis
tocilizumab
work productivity

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1080/14397595.2019.1709681

Cite this

Tanaka, Y., Kameda, H., Saito, K., Kaneko, Y., Tanaka, E., Yasuda, S., Tamura, N., Fujio, K., Fujii, T., Kojima, T., Anzai, T., Hamada, C., Fujino, Y., Matsuda, S., & Kohsaka, H. (2021). Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. Modern rheumatology, 31(1), 42-52. https://doi.org/10.1080/14397595.2019.1709681

Tanaka, Y, Kameda, H, Saito, K, Kaneko, Y, Tanaka, E, Yasuda, S, Tamura, N, Fujio, K, Fujii, T, Kojima, T, Anzai, T, Hamada, C, Fujino, Y, Matsuda, S & Kohsaka, H 2021, 'Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study', Modern rheumatology, vol. 31, no. 1, pp. 42-52. https://doi.org/10.1080/14397595.2019.1709681

@article{3f40add0d446412cbadf8763b5f89a2e,

title = "Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study",

abstract = "Objectives: We evaluated long-term control of rheumatoid arthritis (RA) in Japanese paid workers (PWs) and house workers (HWs) treated with subcutaneous tocilizumab (TCZ-SC) and explored factors affecting response to TCZ-SC regarding work productivity. Methods: This study collected data from patients with RA in the TCZ-SC +/− conventional synthetic disease-modifying antirheumatic drugs group. Factors affecting the response to tocilizumab regarding work productivity were explored using logistic regression. Differences in quality-adjusted life years (QALYs) between with/without response were analysed by a linear regression. Results: Data were analysed for 357/360 patients. Patients with a ≥ 75% improvement in activity impairment (AI) were considered responders. EuroQol-5 Dimension (EQ-5D), six-item Kessler psychological distress scale score (K6), Health Assessment Questionnaire Disability Index (HAQ-DI), and the patient{\textquoteright}s disease global health by visual analogue scale were significant contributors to TCZ-SC response based on improvements in AI. Work Functioning Impairment Scale, presenteeism, EQ-5D, K6, and HAQ-DI significantly contributed to the improvement of overall work impairment in PWs. Shorter disease duration also was related to TCZ-SC response based on AI improvements. Responders had significantly larger mean QALYs than non-responders (difference = 0.2614; p <.001). Conclusions: These real-world clinical data support long-term work productivity control with TCZ-SC for biologic-na{\"i}ve HWs and PWs with RA.",

keywords = "Activity impairment, patient-reported outcome, rheumatoid arthritis, tocilizumab, work productivity",

author = "Yoshiya Tanaka and Hideto Kameda and Kazuyoshi Saito and Yuko Kaneko and Eiichi Tanaka and Shinsuke Yasuda and Naoto Tamura and Keishi Fujio and Takao Fujii and Toshihisa Kojima and Tatsuhiko Anzai and Chikuma Hamada and Yoshihisa Fujino and Shinya Matsuda and Hitoshi Kohsaka",

note = "Publisher Copyright: {\textcopyright} 2020 Japan College of Rheumatology.",

year = "2021",

doi = "10.1080/14397595.2019.1709681",

language = "English",

volume = "31",

pages = "42--52",

journal = "Modern rheumatology",

issn = "1439-7595",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - Response to tocilizumab and work productivity in patients with rheumatoid arthritis

T2 - 2-year follow-up of FIRST ACT-SC study

AU - Tanaka, Yoshiya

AU - Kameda, Hideto

AU - Saito, Kazuyoshi

AU - Kaneko, Yuko

AU - Tanaka, Eiichi

AU - Yasuda, Shinsuke

AU - Tamura, Naoto

AU - Fujio, Keishi

AU - Fujii, Takao

AU - Kojima, Toshihisa

AU - Anzai, Tatsuhiko

AU - Hamada, Chikuma

AU - Fujino, Yoshihisa

AU - Matsuda, Shinya

AU - Kohsaka, Hitoshi

PY - 2021

Y1 - 2021

N2 - Objectives: We evaluated long-term control of rheumatoid arthritis (RA) in Japanese paid workers (PWs) and house workers (HWs) treated with subcutaneous tocilizumab (TCZ-SC) and explored factors affecting response to TCZ-SC regarding work productivity. Methods: This study collected data from patients with RA in the TCZ-SC +/− conventional synthetic disease-modifying antirheumatic drugs group. Factors affecting the response to tocilizumab regarding work productivity were explored using logistic regression. Differences in quality-adjusted life years (QALYs) between with/without response were analysed by a linear regression. Results: Data were analysed for 357/360 patients. Patients with a ≥ 75% improvement in activity impairment (AI) were considered responders. EuroQol-5 Dimension (EQ-5D), six-item Kessler psychological distress scale score (K6), Health Assessment Questionnaire Disability Index (HAQ-DI), and the patient’s disease global health by visual analogue scale were significant contributors to TCZ-SC response based on improvements in AI. Work Functioning Impairment Scale, presenteeism, EQ-5D, K6, and HAQ-DI significantly contributed to the improvement of overall work impairment in PWs. Shorter disease duration also was related to TCZ-SC response based on AI improvements. Responders had significantly larger mean QALYs than non-responders (difference = 0.2614; p <.001). Conclusions: These real-world clinical data support long-term work productivity control with TCZ-SC for biologic-naïve HWs and PWs with RA.

AB - Objectives: We evaluated long-term control of rheumatoid arthritis (RA) in Japanese paid workers (PWs) and house workers (HWs) treated with subcutaneous tocilizumab (TCZ-SC) and explored factors affecting response to TCZ-SC regarding work productivity. Methods: This study collected data from patients with RA in the TCZ-SC +/− conventional synthetic disease-modifying antirheumatic drugs group. Factors affecting the response to tocilizumab regarding work productivity were explored using logistic regression. Differences in quality-adjusted life years (QALYs) between with/without response were analysed by a linear regression. Results: Data were analysed for 357/360 patients. Patients with a ≥ 75% improvement in activity impairment (AI) were considered responders. EuroQol-5 Dimension (EQ-5D), six-item Kessler psychological distress scale score (K6), Health Assessment Questionnaire Disability Index (HAQ-DI), and the patient’s disease global health by visual analogue scale were significant contributors to TCZ-SC response based on improvements in AI. Work Functioning Impairment Scale, presenteeism, EQ-5D, K6, and HAQ-DI significantly contributed to the improvement of overall work impairment in PWs. Shorter disease duration also was related to TCZ-SC response based on AI improvements. Responders had significantly larger mean QALYs than non-responders (difference = 0.2614; p <.001). Conclusions: These real-world clinical data support long-term work productivity control with TCZ-SC for biologic-naïve HWs and PWs with RA.

KW - Activity impairment

KW - patient-reported outcome

KW - rheumatoid arthritis

KW - tocilizumab

KW - work productivity

UR - http://www.scopus.com/inward/record.url?scp=85078427571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078427571&partnerID=8YFLogxK

U2 - 10.1080/14397595.2019.1709681

DO - 10.1080/14397595.2019.1709681

M3 - Article

C2 - 31903822

AN - SCOPUS:85078427571

SN - 1439-7595

VL - 31

SP - 42

EP - 52

JO - Modern rheumatology

JF - Modern rheumatology

IS - 1

ER -

Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this